Self-Regulation in the Pharmaceutical Industry: The Exposure of Children and Adolescents to Erectile Dysfunction Commercials

2019 ◽  
Vol 44 (5) ◽  
pp. 765-787
Author(s):  
Denis G. Arnold ◽  
James L. Oakley
Keyword(s):  
Erectile Dysfunction ◽  
Pharmaceutical Industry ◽  
Children And Adolescents ◽  
Negative Impact ◽  
Self Regulation ◽  
Public Disclosure ◽  
Direct To Consumer ◽  
Industry Standard ◽  
Research Findings ◽  
Direct To Consumer Advertising

Abstract Context: Spending on direct-to-consumer advertising (DTCA) for prescription pharmaceuticals has risen to record levels, five times as much as in 1996 in inflation-adjusted dollars. Major health care provider organizations have called for additional regulation of DTCA. These organizations argue that the negative impact of such advertising outweighs the informational value claimed by the pharmaceutical industry. The industry maintains that further restrictions on DTCA are not warranted because it is successfully self-regulating via “guiding principles” for DTCA as certified by firm executives. Methods: The authors measured recent industry spending on DTCA and used regression models of Nielsen Monitor-Plus data to assess pharmaceutical firm self-regulation after the public disclosure of noncompliance with industry self-regulatory principles, specifically regarding the exposure of children and adolescents to broadcast advertisements for erectile dysfunction drugs. Findings: Public disclosure of noncompliance with self-regulatory DTCA standards did not bring advertising into compliance. Results demonstrate that firms failed to meet the industry standard during every quarter of the six-year period of this study. Conclusions: Results support previous research findings that pharmaceutical self-regulation is a deceptive blocking strategy rather than a means for the industry to police itself. Policy recommendations include broadcast restrictions on adult content and deincentivizing DTCA via tax reform.

scholarly journals The introduction of the medicinal partner in direct-to-consumer advertising: Viagra’s contribution to pharmaceutical fetishism and patient-as-consumer discourse in healthcare

2018 ◽  
Vol 2 (2) ◽  
Author(s):  
Janelle Applequist
Keyword(s):  
United States ◽  
Erectile Dysfunction ◽  
Pharmaceutical Industry ◽  
The United States ◽  
Social Meaning ◽  
Pharmaceutical Advertising ◽  
Direct To Consumer ◽  
Look Back ◽  
Market Transaction ◽  
Direct To Consumer Advertising

Pfizer, manufacturer of the erectile dysfunction prescription treatment Viagra, has been a staple in the pharmaceutical advertising arena since broadcast versions of such ads became legally permissible in the United States in 1997. Given that the patent for Viagra is soon set to expire, it is important that research take a look back in an attempt to contextualize the brand’s place in shaping medicinal marketing culture. Of particular interest is the period beginning in 2014, when Viagra’s most unconventional campaign yet began using a tactic that was the first of its kind for the pharmaceutical industry. By removing the actual consumer of the medication from these ads (males), Viagra has paved the way for pharmaceutical advertising to target the medicinal partner. This manuscript reviews the first use of the medicinal partner in the pharmaceutical advertising sector, conducting a textual analysis of Viagra’s use of this mediated relationship. The medicinal partner is the pharmaceutical industry’s attempt to target a patient’s social circle in an effort to promote a discourse that suggests a medicinal remedy for a problem. This analysis describes how social meaning and relationships underlie the market transaction of obtaining a prescription, as has been previously established through the processes of medicalization and pharmaceutical fetishism. These advertisements create belief in the larger sense, meaning Pfizer is infiltrating upon the patient’s process of choice and consumption of medicinal remedies. Viagra is simultaneously encouraging male consumers to celebrate the brand while using female ambassadors to influence the decision to request medicinal intervention.

Prescription Drug Advertising Direct to the Consumer

PEDIATRICS ◽  
1991 ◽  
Vol 88 (1) ◽  
pp. 174-175
Author(s):  
Keyword(s):  
Health Care ◽  
Pharmaceutical Industry ◽  
Prescription Drugs ◽  
Negative Impact ◽  
Drug Advertising ◽  
Specific Product ◽  
Direct To Consumer ◽  
Previous Medication ◽  
Direct To Consumer Advertising

There is a rapidly growing practice within the pharmaceutical industry of advertising prescription products directly to the general public through media, such as television, radio, newspapers, and popular magazines. Proponents of direct-to-consumer advertising of prescription drugs have asserted that advertising is a source of useful information for the patient. However, it is the position of the Academy that patient education regarding prescription drugs is provided best by the physician within the context of patient care and not through advertising that is designed primarily to promote the sale and consumption of a specific product. Such advertising contributes little, if anything, to the quality of health care while posing multiple problems that may be counterproductive to the provision of optimal pharmacotherapy for pediatric patients. The Academy's opposition to direct-to-consumer advertising of prescription drugs stems from its long tradition of advocacy for children and young people, along with a concern regarding the potential negative impact of such advertising on the health care of children and adolescents. The Academy's objection to consumer advertising of specific prescription products does not apply to general health information provided through public service announcements sponsored by the pharmaceutical industry. Prescription drugs are unique in the marketplace in that they are selected for use by the physician rather than by the consumer. They are designated by law to be used within the patient-physician relationship for the protection and welfare of the patient. In choosing a therapeutic agent for a particular patient's illness, a physician takes into consideration a multitude of complex factors, including the patient's diagnosis, medical history, previous medication interolances, adverse drug reactions, possible drug interactions, chemical dependency, and the array of products that potentially may be used.

scholarly journals Cyberbullying as a negative result of cyber-culture of Slovak children and adolescents: selected research findings

2016 ◽  
Vol 4 (2) ◽  
pp. 40-55 ◽  
Author(s):  
Katarína Hollá
Keyword(s):  
Young People ◽  
Children And Adolescents ◽  
Human Behavior ◽  
Latent Class ◽  
Negative Impact ◽  
Information And Communications Technologies ◽  
National Cultures ◽  
Communications Technologies ◽  
Cyber Culture ◽  
Research Findings

Abstract Cyber-culture points out the life in cyberspace and goes beyond national cultures. It is particularly attractive for the young people who use Information and Communications Technologies (ICT) to express their attitudes, values, beliefs and thinking. Those do not need to be necessarily in accordance with the standards of an individual society. Cyberculture becomes dangerous. Great risk lies in cyberbullying that represents negative impact of cyber-culture on human behavior. The aim of the study is to detect cyberbullying as a negative impact of cyber-culture among of Slovak children and adolescents. The research was carried out on a sample of 1619 11-18-year old respondents (average age was 14.51). Results of cyberbullying research carried out using Latent Class Analysis (LCA) have proved the appropriateness of 3-latent-class module. Relative entropy of the module reached 0.915. It was demonstrated that 52.9% of respondents belonged to the group of uninvolved, 42.7% were victims and 4.4% were victims-aggressors. Being a negative consequence of cyber-culture, cyberbullying is a challenge that educators - including other assisting professions - face when educating children and adolescents to orientate in cyberspace, behave responsibly, express themselves in a way that would not interfere others’ integrity and identity (personal and virtual). The study was written under VEGA MŠVVaŠ SR a SAV č. 1/0244/15: “Detekcia a riešenie kyberšikany”.

The Politics of EU Health Policy and the Case of Direct-to-Consumer Advertising for Prescription Drugs

2011 ◽  
Vol 13 (4) ◽  
pp. 586-602 ◽  
Author(s):  
Robert Geyer
Keyword(s):  
Health Policy ◽  
Pharmaceutical Industry ◽  
Prescription Drugs ◽  
Policy Area ◽  
Detailed Review ◽  
Direct To Consumer ◽  
The Future ◽  
Pros And Cons ◽  
Direct To Consumer Advertising ◽  
The Eu

Direct-to-consumer advertising for prescription drugs (DTCA-PD) is currently banned in the EU, but the pharmaceutical industry (supported by key member states and DG Enterprise) made two major attempts to overturn it in the 2000s at the EU level and failed. What does this failure imply for the debates surrounding this policy area and EU health policy in general? To explore this question, this article will define DTCA-PD, examine its pros and cons, provide a brief overview of EU health policy and present a detailed review of the two recent attempts to overturn the ban. Following this, it will examine the five key elements of EU health policy, evaluate their relevance to the development of the EU's policy towards DTCA-PD and briefly speculate on the future of the ban.

Sign in / Sign up

Export Citation Format

Share Document